Current Gastroenterology Reports最新文献_第2页

Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD. 补充和替代药物（CAM）药物在IBD中的选择性使用。

Current Gastroenterology Reports Pub Date : 2025-01-17 DOI: 10.1007/s11894-025-00960-0

Monica Dzwonkowski, Janak Bahirwani, Samantha Rollins, Alicia Muratore, Vikram Christian, Yecheskel Schneider

{"title":"Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD.","authors":"Monica Dzwonkowski, Janak Bahirwani, Samantha Rollins, Alicia Muratore, Vikram Christian, Yecheskel Schneider","doi":"10.1007/s11894-025-00960-0","DOIUrl":"10.1007/s11894-025-00960-0","url":null,"abstract":"Purpose of review: Inflammatory bowel disease (IBD) can cause significant psychological, physical, and economic burdens on patients and healthcare systems. Studies show over one-fifth of patients will seek nontraditional methods of treatment for managing their symptoms. Understanding the benefits - and potential harms - of these therapies is important to provide holistic and evidence-based care to our IBD patients.Recent findings: In this review, we present several studied herbal therapies for the management of both Crohn's disease and ulcerative colitis. These include cannabinoids, Tripterygium wilfordii, Chios mastic gum, Boswellia serrata, Indigo Naturalis, curcumin, resveratrol, and Zingiber officinale. While these herbal remedies have been shown to have anti-inflammatory effects and positive outcomes in IBD patients, larger scale studies are lacking and the use may be limited by bioavailability, lack of standardization of formulations, and adverse reactions. In reviewing the literature, we discuss the current data available including benefits, adverse reactions, and considerations for use surrounding several of the more common herbal remedies used for IBD.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Vascular Complications from Button Battery Ingestions. 纽扣电池误食血管并发症的处理。

Current Gastroenterology Reports Pub Date : 2025-01-17 DOI: 10.1007/s11894-024-00957-1

Anamika Saha, Elizabeth A Berg, Diana Lerner, Robert Kramer, Christopher Nemeh, Jennifer DeFazio, Ali A Mencin

{"title":"Management of Vascular Complications from Button Battery Ingestions.","authors":"Anamika Saha, Elizabeth A Berg, Diana Lerner, Robert Kramer, Christopher Nemeh, Jennifer DeFazio, Ali A Mencin","doi":"10.1007/s11894-024-00957-1","DOIUrl":"https://doi.org/10.1007/s11894-024-00957-1","url":null,"abstract":"Purpose: To propose a gastrointestinal bleeding management algorithm that incorporates an endoscopic and imaging scoring system and specifies management of vascular complication from button battery ingestion.Recent findings: Button batteries (BB) are found in many electronic devices and ingestions are associated with serious complications especially in cases of unwitnessed ingestions, prolonged impaction, and in children less than 5 years of age. Gastrointestinal bleeding from BB related vascular injury is rare but often rapidly fatal, with a mortality rate as high as 81%. There are no evidence-based guidelines for managing vascular complications from button battery ingestions. This paper proposes a management algorithm that 1) incorporates both an endoscopic and imaging scoring system to guide initial, post procedure, and discharge care and 2) specifies management of button battery related vascular bleeding. The endoscopic score is a modified Zargar classification with added categories for suspected aneurysm and tracheoesophageal fistula. Surgical and endovascular interventions for vascular injury are also reviewed. Until evidence-based guidelines can be developed, hospitals should have a multidisciplinary protocol based on institutional expertise to rapidly manage BB related vascular injury. Prevention of BB related injury offers the best hope of preventing serious complications and should include increasing public awareness and improving safety standards by working with industry and government.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frailty: An Underappreciated Risk Factor for IBD Complications. 虚弱：被忽视的 IBD 并发症风险因素。

Current Gastroenterology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-05 DOI: 10.1007/s11894-024-00945-5

Ananya Venkatesh, Ammu T Susheela, Bharati Kochar

引用次数: 0

Perspectives and Advice from an Interventional Gastroenterologist at a Tertiary Academic Center. 一位三级学术中心介入胃肠病学家的观点和建议。

Current Gastroenterology Reports Pub Date : 2024-12-01 Epub Date: 2024-08-20 DOI: 10.1007/s11894-024-00944-6

Salmaan Jawaid

引用次数: 0

Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks. 肝硬化患者的质子泵抑制剂：药代动力学、优点和缺点。

Current Gastroenterology Reports Pub Date : 2024-12-01 Epub Date: 2024-08-21 DOI: 10.1007/s11894-024-00943-7

Gasser El-Azab

{"title":"Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks.","authors":"Gasser El-Azab","doi":"10.1007/s11894-024-00943-7","DOIUrl":"10.1007/s11894-024-00943-7","url":null,"abstract":"Purpose of review: This review explores the pharmacokinetics, benefits, and risks of proton pump inhibitors (PPIs) in cirrhotic patients, focusing on the appropriateness of their use and potential adverse effects.Recent findings: Recent studies highlight significant pharmacokinetic alterations in PPIs among cirrhotic patients, with marked increases in lansoprazole and pantoprazole exposure and relatively stable levels of esomeprazole. While effective for managing acid-related disorders and post-band ulcer rebleeding, evidence supporting PPI use for portal hypertension-related bleeding is lacking. Emerging research suggests potential adverse effects such as hepatic decompensation, spontaneous bacterial peritonitis, hepatic encephalopathy, and increased mortality, possibly linked to dysbiosis and bacterial translocation. PPI use in cirrhotic patients alters pharmacokinetics significantly, with esomeprazole potentially safer in advanced cirrhosis. The review advises caution in routine PPI use beyond acid-related conditions due to limited evidence and substantial risks. It underscores the need for careful risk-benefit assessments and exploration of alternative therapies. Future research should aim to identify safer management strategies for portal hypertension complications and to develop evidence-based guidelines for PPI use in patients with cirrhosis.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"323-334"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Generative AI in Pediatric Gastroenterology. 小儿胃肠病学中的生成式人工智能。

Current Gastroenterology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-07 DOI: 10.1007/s11894-024-00946-4

John M Rosen

{"title":"Generative AI in Pediatric Gastroenterology.","authors":"John M Rosen","doi":"10.1007/s11894-024-00946-4","DOIUrl":"10.1007/s11894-024-00946-4","url":null,"abstract":"Purpose of review: The integration of digital technology into medical practice is often thrust upon clinicians, with standards and routines developed long after initiation. Clinicians should endeavor towards a basic understanding even of emerging technologies so that they can direct its use. The intent of this review is to describe the current state of rapidly evolving generative artificial intelligence (GAI), and to explore both how pediatric gastroenterology practice may benefit as well as challenges that will be faced.Recent findings: Although little research demonstrating the acceptance, practice, and outcomes associated with GAI in pediatric gastroenterology is published, there are relevant data adjacent to the specialty and overwhelming potential as professed in the media. Best practice guidelines are widely developed in academic publishing and resources to initiate and improve practical user skills are prevalent. Initial published evidence supports broad acceptance of the technology as part of medical practice by clinicians and patients, describes methods with which higher quality GAI can be developed, and identifies the potential for bias and disparities resulting from its use. GAI is broadly available as a digital tool for incorporation into medical practice and holds promise for improved quality and efficiency of care, but investigation into how GAI can best be used remains at an early stage despite rapid evolution of the technology.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"342-348"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medical Media in Pediatric Gastroenterology and Hepatology: Strategies for Effective Use by Consumers, Contributors, and Creators. 儿科胃肠病学和肝病学中的医学媒体：消费者、投稿人和创作者的有效使用策略》。

Current Gastroenterology Reports Pub Date : 2024-12-01 Epub Date: 2024-10-17 DOI: 10.1007/s11894-024-00947-3

Temara Hajjat, Paul Tran

{"title":"Medical Media in Pediatric Gastroenterology and Hepatology: Strategies for Effective Use by Consumers, Contributors, and Creators.","authors":"Temara Hajjat, Paul Tran","doi":"10.1007/s11894-024-00947-3","DOIUrl":"10.1007/s11894-024-00947-3","url":null,"abstract":"Purpose of the review: This review article explores the role of medical media in gastroenterology and hepatology, highlighting its benefits for enhancing clinical practice, education, and patient engagement. It also provides practical guidance for gastroenterologists and hepatologists on effectively implementing these tools in their daily practice.Recent findings: Recent findings highlight that medical media significantly boosts citation rates and dissemination of research, enhances promotional efforts, and fosters greater engagement from patients and trainees. These advances underscore the growing role of medical media in amplifying academic impact and improving educational outreach in gastroenterology and hepatology. Integrating medical media into pediatric gastroenterology and hepatology offers numerous benefits, from enhanced education and professional development to improved patient engagement. By understanding the roles of contributor, creator, and consumer and leveraging the right platforms and content types, pediatric gastroenterologists and hepatologists can effectively utilize medical media to advance their field and provide better care.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"349-359"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yoga in Pediatric Gastroenterology. 小儿肠胃病学瑜伽。

Current Gastroenterology Reports Pub Date : 2024-12-01 Epub Date: 2024-08-13 DOI: 10.1007/s11894-024-00941-9

Francis Peropat, Mazen I Abbas, Maria E Perez, Elizabeth L Yu, Alycia Leiby

{"title":"Yoga in Pediatric Gastroenterology.","authors":"Francis Peropat, Mazen I Abbas, Maria E Perez, Elizabeth L Yu, Alycia Leiby","doi":"10.1007/s11894-024-00941-9","DOIUrl":"10.1007/s11894-024-00941-9","url":null,"abstract":"Purpose of review: Pediatric use of yoga as an integrative medicine modality has increased in prevalence over the last several decades. In this article, we review the available evidence for yoga in pediatric gastrointestinal disorders.Recent findings: Evidence supports that in many pediatric disorders of gut brain interaction (DGBI), including irritable bowel syndrome, functional abdominal pain and functional dyspepsia, yoga decreases pain intensity and frequency and increases school attendance. Yoga has been shown to improve health-related quality of life and improve stress management as an effective adjunct to standard medical therapy in pediatric inflammatory bowel disease (IBD). Further studies are needed regarding optimal frequency, duration of practice and evaluation of the impact on IBD disease activity measures. Yoga may benefit pediatric gastroenterology patients with DGBIs and IBD through improving quality of life and reducing pain. Future yoga studies could investigate biomarkers and continued research will help integrate this modality into routine pediatric gastroenterology care.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"335-341"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. 钾竞争性胃酸阻滞剂：当前的临床应用和未来发展。

Current Gastroenterology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-15 DOI: 10.1007/s11894-024-00939-3

Carmelo Scarpignato, Richard H Hunt

{"title":"Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.","authors":"Carmelo Scarpignato, Richard H Hunt","doi":"10.1007/s11894-024-00939-3","DOIUrl":"10.1007/s11894-024-00939-3","url":null,"abstract":"Purpose of the review: Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice.Recent findings: Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs. Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that-in the above two clinical indications-P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"273-293"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Virtual Reality in the Management of Irritable Bowel Syndrome. 虚拟现实技术在肠易激综合征治疗中的作用。

Current Gastroenterology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-13 DOI: 10.1007/s11894-024-00940-w

Karisma K Suchak, Christopher V Almario, Omer Liran, Robert Chernoff, Brennan R Spiegel

{"title":"The Role of Virtual Reality in the Management of Irritable Bowel Syndrome.","authors":"Karisma K Suchak, Christopher V Almario, Omer Liran, Robert Chernoff, Brennan R Spiegel","doi":"10.1007/s11894-024-00940-w","DOIUrl":"10.1007/s11894-024-00940-w","url":null,"abstract":"Purpose of review: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction that significantly impacts health-related quality of life (HRQOL). This article explores the potential role of virtual reality (VR)-based cognitive behavioral therapy (CBT) in treating patients with IBS.Recent findings: While CBT is a proven, skills-based therapy approach that modifies behaviors and alters dysfunctional thinking patterns to influence the gut-brain axis and improve IBS symptoms, it is rarely prescribed given a paucity of CBT-trained clinicians. We developed a novel VR program that delivers a standardized CBT program over an 8-week period to help patients manage their symptoms. In initial qualitative validation testing, patients expressed positive perceptions about using VR CBT for IBS. Home-based, standardized VR CBT has the potential to be an effective and scalable treatment option for patients with IBS. While initial studies have shown proof-of-concept definitive randomized controlled trials are needed to demonstrate the efficacy of self-administered VR CBT in IBS.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"294-303"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0